anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Despite immunization, patients on antineoplastic and immunomodulating agents have a heightened risk of COVID-19 infection. However, accurately attributing this risk to specific medications remains challenging.
METHODS: An observational cohort study from December 11, 2020 to September 22, 2022, within a large healthcare system in San Diego, California, USA was designed to identify medications associated with greatest risk of postimmunization SARS-CoV-2 infection. Adults prescribed WHO Anatomical Therapeutic Chemical (ATC) classified antineoplastic and immunomodulating medications were matched (by age, sex, race, and number of immunizations) with control patients not prescribed these medications yielding a population of 26 724 patients for analysis. From this population, 218 blood samples were collected from an enrolled subset to assess serological response and cytokine profile in relation to immunization.
RESULTS: Prescription of WHO ATC classified antineoplastic and immunomodulatory agents was associated with elevated postimmunization SARS-CoV-2 infection risk (HR 1.50, 95% CI 1.38 to 1.63). While multiple immunization doses demonstrated a decreased association with postimmunization SARS-CoV-2 infection risk, antineoplastic and immunomodulatory treated patients with four doses remained at heightened risk (HR 1.23, 95% CI 1.06 to 1.43). Risk variation was identified among medication subclasses, with PD-1/PD-L1 inhibiting monoclonal antibodies, calcineurin inhibitors, and CD20 monoclonal antibody inhibitors identified to associate with increased risk of postimmunization SARS-CoV-2 infection. Antineoplastic and immunomodulatory treated patients also displayed a reduced IgG antibody response to SARS-CoV-2 epitopes alongside a unique serum cytokine profile.
CONCLUSIONS: Antineoplastic and immunomodulating medications associate with an elevated risk of postimmunization SARS-CoV-2 infection in a drug-specific manner. This comprehensive, unbiased analysis of all WHO ATC classified antineoplastic and immunomodulating medications identifies medications associated with greatest risk. These findings are crucial in guiding and refining vaccination strategies for patients prescribed these treatments, ensuring optimized protection for this susceptible population in future COVID-19 variant surges and potentially for other RNA immunization targets.
The invention discloses application of bacillus megatherium strain SI-JD-01 in preparing an anti-inflammatory and antioxidant product and a prepared skin care product, and belongs to the technical field of microorganism application. The preservation number of the bacillus megaterium strain SI-JD-01 is CCTCC No: m2023278. The product comprises one or more of food, medicine, health product and cosmetic. The strain SI-JD-01 has the capability of reducing the expression level of inflammatory factors IL-1 beta and eliminating ABTS free radicals and macrophage ROS. The beneficial effects are that: the bacillus megatherium SI-JD-01 has good antioxidation effect, high ABTS free radical clearance rate and reduced macrophage ROS content; meanwhile, the anti-inflammatory agent has the capability of highly inhibiting macrophage inflammatory factor IL-1 beta caused by LPS, and can obviously reduce the expression of macrophage IL-1 beta caused by LPS. The strain has good application prospect in resisting skin injury caused by free radicals, resisting skin injury caused by inflammatory factors and developing antioxidant and anti-inflammatory products.
PROBLEM TO BE SOLVED: To obtain an acidic semipermanent hair dyeing material composition for an aerosol spray, excellent in dyeing property, eliminating a dripping down of the dyeing material composition during the dyeing, not polluting a scalp, etc., and simple in applying operation. SOLUTION: This acidic semipermanent hair dyeing material composition for an aerosol spray is to fill a material blended with the acidic semipermanent dyeing material stock solution containing an acid dye, a penetration accelerating agent, a viscosity adjusting agent, a foam quality stabilizing agent, etc., with a propellant simultaneously into an aerosol container equipped with an applicator such as a comb or a brush and use it by spraying in a foam state. At that time, it is necessary to eliminate the foam so that the density of the foam becomes >=0.1g/ml at 25 deg.C under an atmospheric pressure within 10sec after spraying. Also, in this case, the viscosity of the acidic semipermanent dyeing material stock solution is preferably made to be 1000-5000cs. Based on 100 pts.wt. acidic semipermanent hair dyeing material stock solution, 0.1-20 pts.wt. propellant is blended.  The concentration of the acid in the stock solution is set to >=0.01g equivalent/l in the case of expressing the acid concentration by a buffering capacity.
BACKGROUND: Most schwannomas are isolated tumours occurring in otherwise healthy people. However, bilateral vestibular schwannomas (BVS) or multiple non-vestibular schwannomas indicate an underlying genetic predisposition. This is most commonly NF2-related schwannomatosis (SWN), but when BVS are absent, this can also indicate SMARCB1-related or LZTR1-related SWN.
METHODS: We assessed the variant detection rates for the three major SWN genes (NF2, LZTR1 and SMARCB1) in 154 people, from 150 families, who had at least one non-vestibular schwannoma, but who did not meet clinical criteria for NF2-related SWN at the time of genetic testing.
RESULTS: We found that 17 (11%) people from 13 families had a germline SMARCB1 variant and 19 (12%) unrelated individuals had a germline LZTR1 variant. 19 people had an NF2 variant, but 18 of these were mosaic and 17 were only detected when 2 tumours were available for testing. The overall detection rate was 25% using blood alone, but increased to 36% when tumour analysis was included. Another 12 people had a germline variant of uncertain significance (VUS).
CONCLUSIONS: There were similar proportions of LZTR1, SMARCB1 or mosaic NF2. However, since an NF2 variant was detected in tumours from 103 people, it is likely that further cases of mosaicism would be detected if more people had additional tumours available for analysis. In addition, if further evidence becomes available to show that the VUSs are pathogenic, this would significantly increase the proportion of people with a genetic diagnosis. Our results indicate the importance of comprehensive genetic testing and improved variant classification.
PURPOSE:To obtain a lipoxygenase inhibitor, containing a compound contained in spikes of a herb medicine Nepetae Herba as an active ingredient and effective in treating circulatory diseases such as allergic disease, inflammation, arteriosclerosis or cardiac infarction. CONSTITUTION:The objective substance is obtained by including a compound expressed by formula I (A is rutinose), formula II (R1 and R2 are H, glucose or glucuronic acid), formula III (R3 is H or methyl) or formula V (R4 is R3) as an active ingredient, further suitably blending other normally used pharmaceutical ingredients with the active ingredient and preparing a pharmaceutical according to a conventional method. The aforementioned substance can be prepared into the form such as an oral agent such as tablet, capsule, granule, fine granule or powder or a parenteral agent such as injection or suppository. The dose for an adult per day expressed in terms of the weight of the compound expressed by formula I to IV is 30mg to 3g in the case of oral administration and 0.1-500 mg in the case of parenteral administration. The compound expressed by formula I to IV is obtained by extracting spikes of Nepetae Herba (the family Labiatae) with a solvent (e.g. water-methanol), then fractionating and purifying the resultant extract by a well-known method.
Viruses normally reprogram the host cell metabolic pathways as well as metabolic sensors to facilitate their persistence. The serine-threonine liver kinase B1 (LKB1) is a master upstream kinase of 5'-AMP-activated protein kinase (AMPK) that senses the energy status and therefore regulates the intracellular metabolic homeostasis. Previous studies showed that AMPK restricts Kaposi's sarcoma-associated herpesvirus (KSHV) lytic replication in endothelial cells during primary infection and promotes primary effusion lymphoma (PEL) cell survival. However, the role of LKB1 in KSHV lytic reactivation and KSHV-associated malignancies is unclear. In this study, we found that LKB1 is phosphorylated or activated in KSHV-positive PEL cells. Mechanistically, KSHV-encoded vCyclin mediated LKB1 activation in PEL cells, as vCyclin knockout ablated, while vCyclin overexpression enhanced LKB1 activation. Furthermore, knockdown of LKB1 inactivated AMPK and induced KSHV reactivation, as indicated by the increased expression of viral lytic genes and the increased virions in supernatants. Accordingly, AMPK inhibition by functional knockdown or a pharmacologic inhibitor, Compound C, promoted KSHV reactivation in PEL cells. Furthermore, inhibition of either LKB1 or AMPKα1 efficiently induced cell death by apoptosis of PEL cells both in vitro and in vivo. Together, these results identify LKB1 as a vulnerable target for PEL, which could be potentially exploited for treating other virus-associated diseases.IMPORTANCEKaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic virus associated with several human cancers, such as primary effusion lymphoma (PEL). Here, we showed that serine-threonine liver kinase B1 (LKB1), upstream of 5' AMP-activated protein kinase (AMPK), is activated by KSHV-encoded vCyclin and maintains KSHV latency in PEL cells. Inhibition of either LKB1 or AMPK enhances KSHV lytic replication from latency, which at least partially accounts for PEL cell death by apoptosis. Compound C, a potent AMPK inhibitor, induced KSHV reactivation and efficiently inhibited PEL progression in vivo. Thus, our work revealed that LKB1 is a potential therapeutic target for KSHV-associated cancers.
Myocardial ischemia-reperfusion (I/R) injury caused by revascularization treatment is the leading cause of cardiac damage aggravation in ischemic heart disease. Increasing evidence has unraveled the crucial role of pyroptosis in myocardial I/R injury. Of note, lactylation has been validated to be participated in modulating pyroptosis. Hence, this study was aimed to elaborate the potential and mechanism of lactylation in myocardial I/R damage. We established the cell model of I/R through inducing hypoxia/reoxygenation (H/R) of H9c2 cells. It was uncovered that H/R stimulation drove cardiomyocyte pyroptosis and upregulated total lactylation level. Further, we demonstrated that promoting lactylation contributed to H/R-evoked pyroptosis, whereas silencing LDHA led to the opposite results. More than that, LDHA was confirmed to facilitate lactylation of NLRP3 at K245 site and increase its protein stability. Our findings indicated that activation of NLRP3 abolished the function of LDHA deficiency in H/R-treated H9c2 cells. In concert with the aforementioned outcomes, knockout of LDHA attenuated the infarct size and myocardial damage in I/R mice and upregulation of NLRP3 counteracted the effects of LDHA knockout on I/R-evoked injury in vivo. To summarize, the current research provided persuasive evidence that LDHA promoted myocardial I/R damage via enhancing NLRP3 lactylation to induce cardiomyocyte pyroptosis.
PURPOSE:To obtain the titled agent free from side effect such as hepatic disorder and having excellent effect, by using one or more compounds selected from 9,12,15-cis-octadecatrienoic acid and 5,8,11,14-cis-eicosatetraenoic acid as an active component. CONSTITUTION:The objective agent contains one or more compounds selected from 9,12,15-cis-octadecatrienoic acid, its acid derivative, 5,8,11,14-cis- eicosatetraenoic acid and its acid derivative as active components. The above active compound is mixed with a conventional preparation raw material such as gelatin, casein or lactose and formed in the form suitable for oral administration or subcutaneous injection, etc. (e.g. capsule or tablet). The amount of the active compound in the drug preparation is >=0.1g per 1kg of the body weight. The active compound is present at a small amount as a fatty acid composition in natural oils and fats such as linseed oil or soybean oil.
A spray delivery system including a sprayable active agent composition housed within a container is provided that can be used in the treatment of various skin conditions. The composition includes a hydrofluoro-based propellant, a carrier fluid, and active agent particles, and has a viscosity ranging from about 500 centipoise to about 10,000 centipoise. The container includes a dip tube; a valve assembly that includes a valve body, a stem comprising a stem orifice, and a vapor tap; and an actuator. The dip tube is coupled to the actuator by the valve assembly, and the actuator is depressed to dispense the emulsion. By selectively controlling the components and viscosity of the composition and the dimensions of the container components, the active agent particles resist settling so a substantially homogeneous distribution of the particles is maintained. Thus, the composition can be evenly dispensed from the container as a fine mist without clogging.
BACKGROUND: Because of advances in medical treatment of heart failure, patients are living longer than in previous eras and may approach the need for advanced therapies, including heart transplantation, at older ages. This study assesses practices surrounding heart transplant in older adults (> 70 years) and examines short- and medium-term outcomes.
METHODS AND RESULTS: This study is a retrospective analysis using the United Network for Organ Sharing (UNOS) database from 2010 to 2021. The absolute number of older adults being transplanted is increasing. Older adults were more likely to have had a prior malignancy or ischemic cardiomyopathy and less likely to be on extra-corporeal membrane oxygenation or have a high UNOS status prior to transplant. Mortality at 1-year was higher for older adults (27.8% vs. 23.4%), but at 5 years there was no significant difference (22.3% vs. 19.4%.). Older adults were more likely to die of malignancy or infection. Adults under 70 were more likely to die of cardiovascular causes or graft failure. There was less rejection in older adults. Mortality has not changed for older adults transplanted before versus after the 2018 UNOS allocation change.
CONCLUSIONS: Carefully selected older adults may be considered for heart transplantation, given similar intermediate-term mortality.
A recombinant VLP-antibody (VLP-Ab) comprising a modified hepadnaviral envelope fusion protein comprising an antibody variable domain. The variable domain may be selected from an antibody heavy chain variable domain and a light chain variable domain. In some embodiments, the variable domain (the first variable domain) is bound to a complementary antibody variable domain of a second variable domain protein and forms the antibody antigen binding site specific for a target molecule. One second variable domain protein may be a modified hepadnaviral envelope fusion protein comprising a complementary antibody variable domain. The VLP-Ab may comprises a modified hepadnaviral envelope fusion protein comprising a heterologous antigen. One modified hepadnaviral envelope fusion protein is a hepatitis B envelope protein or a VLP-forming part or variant thereof. A eukaryotic expression vector comprising a recombinant nucleic acid molecule encoding a hepadnavirus envelope-antibody fusion protein comprising an antibody variable domain wherein the variable domain is selected from an antibody heavy chain variable domain and a light chain variable domain. A eukaryotic expression vector comprising a recombinant nucleic acid molecule encoding a second variable domain protein comprising an antibody variable domain wherein the variable domain is selected from an antibody heavy chain variable domain and a light chain variable domain. The expression vector may encode a single variable domain selected from an antibody heavy chain variable domain and a light chain variable domain. The expression vector may encode an Sc Fv. A eukaryotic expression vector operably linked to a polynucleotide encoding a hepadnavirus envelope-antibody fusion protein comprising and an antibody variable domain (EAFP) wherein the antibody variable domain is selected from an antibody heavy chain variable domain and a light chain variable domain, and further capable of expressing a second polynucleotide encoding a second variable domain protein comprising a complementary antibody variable domain. An isolated eukaryotic cell comprising the expression vector. Pharmaceutical and diagnostic compositions are provided and a wide range of therapeutic or prophylactic uses and methods. The manufacture of a medicament for, the treatment or prevention of an infection of a subject by a pathogen, or an inflammatory, immunity or cancer-related condition in a subject. A method for preparing a VLP-Ab, the method comprising transfecting a eukaryotic cell with an expression vector as described, culturing the cell in vitro for a time and under conditions sufficient to permit VLP-Ab formation and optionally secretion, and at least partly purifying the VLP-Ab from the cell culture material.
The invention relates to a traditional Chinese medicine composition for treating blood stasis syndrome during multi-organ dysfunction syndrome and a preparation thereof and belongs to the filed of traditional Chinese medicine. The traditional Chinese medicine composition for treating the multi-organ dysfunction syndrome is prepared by extracting the following raw materials by weight proportion: 80-120 parts of membranous milkvetch root, 40-60 parts of danshen root, 10-20 parts of Szechuan lovage rhizome, 10-20 parts of red paeony root, 10-20 parts of safflower and 10-20 parts of Chinese angelica. The traditional Chinese medicine composition has the advantage that: the traditional Chinese medicine composition is an experience formula which is summed up by years of clinical practices. The formula has no highly toxic drug and no compatibility contraindication, and the using amount is in the stipulated scope of pharmacopoeia. The long-term clinical application does not find the toxic and adverse reactions, and the preparation of the formula has no toxic reaction on the animal formulation toxicity test. When in treatment of MODS and MSOF over the years, the efficacy is significantly improved and the mortality rate is reduced.
AIMS: Anticoagulation can prevent stroke and prolong lives in patients with atrial fibrillation (AF). However, anticoagulated patients with AF remain at risk of death. The aim of this study was to investigate the causes of death and factors associated with all-cause and cardiovascular death in the XANTUS population.
METHODS AND RESULTS: Causes of death occurring within a year after rivaroxaban initiation in patients in the XANTUS programme studies were adjudicated by a central adjudication committee and classified following international guidance. Baseline characteristics associated with all-cause or cardiovascular death were identified. Of 11 040 patients, 187 (1.7%) died. Almost half of these deaths were due to cardiovascular causes other than bleeding (n = 82, 43.9%), particularly heart failure (n = 38, 20.3%) and sudden or unwitnessed death (n = 24, 12.8%). Fatal stroke (n = 8, 4.3%), which was classified as a type of cardiovascular death, and fatal bleeding (n = 17, 9.1%) were less common causes of death. Independent factors associated with all-cause or cardiovascular death included age, AF type, body mass index, left ventricular ejection fraction, hospitalization at baseline, rivaroxaban dose, and anaemia.
CONCLUSION: The overall risk of death due to stroke or bleeding was low in XANTUS. Anticoagulated patients with AF remain at risk of death due to heart failure and sudden death. Potential interventions to reduce cardiovascular deaths in anticoagulated patients with AF require further investigation, e.g. early rhythm control therapy and AF ablation.
TRIAL REGISTRATION NUMBERS: NCT01606995, NCT01750788, NCT01800006.
The invention relates to the technical field of microorganisms, and provides Penicillium roqueforti (Penicillium roqueforti) with a preservation number of CGMCC No. 14140. The Penicillium roqueforti provided by the invention is derived from the root of aconitum vilmorinianum and is an endophytic fungus of aconitum vilmorinianum. The metabolite of the penicillium roqueforti contains a sesterterpene compound peniroquesine A with a novel 5/6/5/6/5 pentacyclic new framework structure, and has obvious anti-inflammatory activity. The penicillium roqueforti provided by the invention can be used for simply and efficiently preparing sesterterpene compound peniroquesine A for preparing anti-inflammatory drugs. The method for preparing the sesterterpene compounds by microbial fermentation has the advantages of short period, mild culture conditions, few byproducts, strong stereoselectivity and low cost.
1526852 Collagenous compositions WARNER-LAMBERT CO 30 Jan 1976 [18 Feb 1975] 03742/76 Heading C3H An aqueous collagen suspension, comprising acidic collagen and bovine serum albumin is claimed per se. A method of preparing such a collagen composition comprises the steps of hydrating an amount of collagen at about 4‹ C. in an amount of acid; homogenizing the hydrated material; centrifuging the homogenized material; stirring the centrifuged material; filtering the stirred material; and diluting the filtered material with an amount of bovine serum albumin sufficient to give a concentration of from 5 to 1000 Ág. of collagen per ml. of diluted solution. The aqueous suspension may also comprise acetic acid, and its pH may be 3À0 to 4À5. Subsequently the diluted solution of collagen to which bovine serum albumin has been added may be lyophilized.
Anthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of anthracycline therapy. Identification of genes and genetic variants associated with AIC risk has clinical potential as a cardiotoxicity predictive tool and to allow the development of personalized therapies. In this review, we provide an overview of the function of known AIC genes identified by association studies and categorize them based on their mechanistic implication in AIC. We also discuss the importance of functional validation of AIC-associated variants in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to advance the implementation of genetic predictive biomarkers. Finally, we review how patient-specific hiPSC-CMs can be used to identify novel patient-relevant functional targets and for the discovery of cardioprotectant drugs to prevent AIC. Implementation of functional validation and use of hiPSC-CMs for drug discovery will identify the next generation of highly effective and personalized cardioprotectants and accelerate the inclusion of approved AIC biomarkers into clinical practice.
Verapamil hydrochloride affects the AV and SA nodes and rarely may produce second- or third-degree AV block, bradycardia, and, in extreme cases, asystole. This is more likely to occur in patients with a sick sinus syndrome (SA nodal disease), which is more common in older patients. Bradycardia associated with sick sinus syndrome was reported in 0.3% of the patients treated in controlled double-blind trials in the U.S. The total incidence of bradycardia (ventricular rate less than 60 beats/min) was 1.2% in these studies. Asystole in patients other than those with sick sinus syndrome is usually of short duration (few seconds or less), with spontaneous return to AV nodal or normal sinus rhythm. If this does not occur promptly, appropriate treatment should be initiated immediately. (See ADVERSE REACTIONS and Suggested Treatment of Acute Cardiovascular Adverse Reactions)
Subjects in the control group also received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.